Background. The inability to visualize the patient and surgical site directly, limits the use of current near infrared fluorescence-guided surgery systems for real-time sentinel lymph node biopsy and tumor margin assessment. Methods. We evaluated an optical see-through goggle augmented imaging and navigation system (GAINS) for near-infrared, fluorescence-guided surgery. Tumor-bearing mice injected with a near infrared cancer-targeting agent underwent fluorescence-guided, tumor resection. Female Yorkshire pigs received hind leg intradermal indocyanine green injection and underwent fluorescence-guided, popliteal lymph node resection. Four breast cancer patients received 99m Tc-sulfur colloid and indocyanine green retroareolarly before undergoing sentinel lymph node biopsy using radioactive tracking and fluorescence imaging. Three other breast cancer patients received indocyanine green retroareolarly before undergoing standard-of-care partial mastectomy, followed by fluorescence imaging of resected tumor and tumor cavity for margin assessment.
ABSTRACT
Background. The inability to visualize the patient and surgical site directly, limits the use of current near infrared fluorescence-guided surgery systems for real-time sentinel lymph node biopsy and tumor margin assessment. Methods. We evaluated an optical see-through goggle augmented imaging and navigation system (GAINS) for near-infrared, fluorescence-guided surgery. Tumor-bearing mice injected with a near infrared cancer-targeting agent underwent fluorescence-guided, tumor resection. Female Yorkshire pigs received hind leg intradermal indocyanine green injection and underwent fluorescence-guided, popliteal lymph node resection. Four breast cancer patients received 99m Tc-sulfur colloid and indocyanine green retroareolarly before undergoing sentinel lymph node biopsy using radioactive tracking and fluorescence imaging. Three other breast cancer patients received indocyanine green retroareolarly before undergoing standard-of-care partial mastectomy, followed by fluorescence imaging of resected tumor and tumor cavity for margin assessment.
Results. Using near-infrared fluorescence from the dyes, the optical see-through GAINS accurately identified all mouse tumors, pig lymphatics, and four pig popliteal lymph nodes with high signal-to-background ratio. In 4 human breast cancer patients, 11 sentinel lymph nodes were identified with a detection sensitivity of 86.67 ± 0.27% for radioactive tracking and 100% for GAINS. Tumor margin status was accurately predicted by GAINS in all three patients, including clear margins in patients 1 and 2 and positive margins in patient 3 as confirmed by paraffin-embedded section histopathology. Conclusions. The optical see-through GAINS prototype enhances near infrared fluorescence-guided surgery for sentinel lymph node biopsy and tumor margin assessment in breast cancer patients without disrupting the surgical workflow in the operating room.
Breast cancer is the most common cancer and the leading cause of cancer death in women in the United States, with breast-conserving surgery (BCS) as the standard-of-care for early-stage breast cancer.
1 BCS is usually accompanied by sentinel lymph node (SLN) biopsy for disease staging, using radioactive and blue dye tracking. [2] [3] [4] [5] [6] [7] However, radioactive tracers expose patients and caregivers to ionizing radiation and require the involvement of nuclear medicine trained personnel, increasing costs and difficulty in scheduling surgery. Additionally, the strict regulatory hurdles prevent the use of radioisotopes in some surgical centers. Although blue dyes can overcome some of these limitations, tissue autofluorescence and shallow penetration of visible light in tissue preclude visualizing deep-seated lymph nodes. 8 These dyes also pose the risk of anaphylactic reactions in 1-3% of patients. 9 Perhaps a greater challenge in BCS is positive margin resection. 10 Approximately 25% of women who undergo BCS have positive surgical margins that can lead to a twofold increase in ipsilateral tumor recurrence. 11 As a result, the presence of positive margins requires repeat operation. Currently, significant variability exists in patient outcomes based on the facility where the surgery is performed, surgeon experience, and patient's age and tumor characteristics. [12] [13] [14] Near-infrared (NIR) fluorescence-guided surgery (FGS) has been shown to facilitate intraoperative SLN biopsy and tumor margin assessment. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Several intraoperative NIR-FGS systems have been developed and tested clinically. 21, [24] [25] [26] [27] [28] [29] However, they often suffer from a large hardware footprint in an already crowded operating room. Typically, the camera's and surgeon's field of view do not match, which necessitates a learning curve for system usage. Current FGS systems display the information on remote monitors that require the surgeon to look away from the surgical bed. Additionally, using handheld devices require the surgeon to stop working or need someone from the surgical team to operate the instrument. The combination of these factors can disrupt standard surgical workflow and may increase surgery time.
We previously developed a goggle augmented imaging and navigation system (GAINS) for real-time NIR FGS that allowed accurate tumor resection in mouse models of cancer and enabled SLN visualization in human breast cancer and melanoma patients with high sensitivity. 8 GAINS detects both anatomic color reflectance and NIR fluorescence from contrast agents, displaying accurately aligned superimposed color-NIR images via a headmounted display (HMD) worn by the surgeon. 8 This system displayed the images in a video-see-through mode, which obstructed direct visualization of the patient. Reliance on a video feed for open surgery minimizes natural visual and tactile skills that surgeons utilize routinely during surgery. Based on the feedback from surgeons, we have developed an optical see-through (OST) HMD system that allows direct visualization of the surgical bed with provision to project fluorescence information directly to the user's eyes. 30 In this study, we performed in vivo evaluation of the OST GAINS prototype in a subcutaneous mouse model of cancer for guiding tumor resection, and lymphatic tracking, and LN resection in a porcine model. We also evaluated the system for SLN biopsy and tumor margin assessment in human breast cancer patients.
METHODS

Fluorescence-Guided Surgery
Real-time, intraoperative, FGS was performed using the OST GAINS prototype (Fig. 1) , which was described in detail earlier. 30 Briefly, the OST GAINS uses a focus-adjustable camera to capture color reflectance and NIR fluorescence and generates accurately aligned color-NIR superimposed images. These images are displayed via a custom OST HMD that allows direct visual access to the surgical field, with contrast-and transparency-adjusted projection of fluorescence information. A 780-nm, 0.8-W laser (B&W Tek, Newark, DE) provides the NIR illumination. White light illumination is provided by standard surgical light (Supplemental Fig. 1 ), covered with a shortpass film filter to minimize the NIR bleed through into the fluorescence detection channel of the GAINS camera. 31 System evaluation is described in Supplementary Methods.
Animal Studies
All animal studies were approved by the Washington University Animal Studies Committee. Three, 6-week-old, Balb/c nu/mu mice were subcutaneously injected with 10 6 prostate neuroendocrine cancer cells (PNEC30, ATCC, Manassas, VA) cells in their left hind flanks. They were injected with a tumor-targeted NIR contrast agent LS301 (0.441 mg/kg) via tail vein injection, 10-12 days after tumor implantation. At 24 h postinjection, the mice were anesthetized using 2% isofluorane and OST GAINS was used for fluorescence-guided tumor resection. All resected tissues were preserved for frozen-section histopathologic analysis.
Three, 35-kg, female Yorkshire pigs received 0.04 mg/ kg atropine and 0.45 mg/kg Telazol, ketamine, and xylazine intramuscularly. Anesthesia was subsequently maintained with isoflurane (1-5% v/v in O 2 ) by intubation. ICG (0.043 mg/kg, Sigma-Aldrich, St. Louis, MO) was injected intradermally into the hind leg. OST GAINS was used to track noninvasively the lymphatic ICG circulation to locate and guide incision and resection of popliteal LNs. Resected LNs were preserved in formalin. All pigs were euthanized by intravenous potassium chloride.
Histology
Fresh-frozen, tissue samples were cryosectioned to create 10-lm tissue sections, which were imaged for NIR fluorescence, followed by hematoxylin and eosin staining. The same areas were then imaged under brightfield for co-registration with NIR fluorescence using an epifluorescence microscope (BX51 Olympus, Center Valley, PA).
Human Pilot Study
The human pilot study was approved by the Institutional Review Board at Washington University and registered on the clinicaltrials.gov website (NCT02316795). Women, with newly diagnosed, clinically node-negative breast cancer, negative nodal basin clinical exam, and scheduled to undergo partial mastectomy with SLN biopsy were enrolled for the study. All patients gave informed consent for this HIPAA-compliant study and data were deidentified.
All patients (n = 7) received a single deposit subcutaneous injection of 99m Tc-sulfur colloid (834 lCi, 1 ml) 2-3 h before surgery. Patients were injected with ICG (25 mg, 5 ml) in the retroareolar breast, peritumorally using 4 deposits around the primary tumor area, followed by site massage for 5 min. Approximately 10-15 min after injection, the surgeon performed standard-of-care SLN biopsy or partial mastectomy. The methods for patients undergoing sentinel lymph node biopsy (n = 4) and those undergoing intraoperative tumor margin assessment (n = 3) are described in Supplementary Methods. The use of both ICG staining and radioactivity enhanced the selective identification of SLNs. Tumor margins were evaluated by specimen radiography before the tumor tissue were preserved for histopathologic evaluation. 32 All OST GAINS components were sterilized by thoroughly wiping the system with sterile, 70% alcohol wipes before entering the operating room for each procedure (see Supplementary Methods for additional information).
Statistical Analysis
Statistical analysis was performed using OriginPro8 (OriginLab Corp., Northampton, MA). Signal-to-background ratios (SBRs) and sensitivity were expressed as mean and standard deviations. Paired t tests were used to compare fluorescence signal for noninvasive and invasive imaging in the mouse model of tumor, fluorescence signal during transcutaneous lymphatic tracking, and exposed lymph nodes in pigs and sensitivity of SLN detection by OST GAINS and radioactive tracking. P \ 0.05 was considered statistically significant.
RESULTS
Tumor Resection in Mice
The OST GAINS allowed direct visual access to the surgical bed while projecting real-time, high-contrast fluorescence information to guide complete tumor resection in three mice (Fig. 1) . Transcutaneous tumor fluorescence was detected with an SBR of 1.45 ± 0.24 and guided incision to expose the tumors. Fluorescence from exposed tumors was detected with an SBR of 1.49 ± 0.13 and guided tumor resection. Both tumor and background fluorescence detected after skin deflection was significantly higher than that observed with intact skin (P \ 0.05 and P \ 0.01), signifying the more reflective nature of the peritoneum. There was no statistically significant difference between the SBR for transcutaneous and exposed tumor fluorescence (P = 0.37; Supplemental Table 1) . Survey of the tumor bed for residual fluorescence showed that no suspected tumor tissue was left behind. All tissue were confirmed to be cancerous by histopathology.
Lymphatic Tracking in Pigs
OST GAINS detected transcutaneous lymphatic fluorescence in three pigs ( Fig. 1 ) with an SBR of 2.74 ± 1.74. Fluorescence lymphatic tracking from injection site successfully guided incision and resection of all popliteal LNs (Video 1) without using radioactive tracking. A total of four popliteal LNs were detected with an SBR of 3.19 ± 1.81 that allowed their accurate resection. Fluorescence from exposed LN as well as background tissue was significantly higher than fluorescence from transcutaneous lymphatics and intact skin (P \ 0.01; Supplemental Table 1 ). The LN SBR was significantly higher than the SBR for transcutaneous lymphatics (P \ 0.05), suggesting that pig peritoneum is less reflective than mouse peritoneum, during NIR imaging.
SLN Biopsy in Human Breast Cancer Patients
Before human use, a surgeon evaluated the OST HMD system in a preclinical operating room using ICG phantom (see Supplementary Results) . The patient characteristics are listed in Table 1 . The direct visual access to the surgical field allowed the surgeon to make tissue incision and resection while wearing the OST GAINS prototype (Fig. 2) . The fluorescence projection to the HMD was turned on when requested by the surgeon for SLN visualization, and its contrast was remotely controlled, based on surgeon feedback and ambient light to ensure visibility of fluorescence as well as underlying tissue (Sup Fig. 2 ). All fluorescence guidance was performed without turning off the surgical lights. No adverse reactions associated with the use of ICG or the OST GAINS prototype occurred and no postoperative complications were observed. A total of 11 SLNs were identified from 4 patients with a mean of 2.2 ± 0.98 SLNs identified per patient ( Table 1 ). The OST GAINS identified 11 (100%) SLNs with a detection sensitivity of 100% and SBR of 2.14 ± 0.83 (Table 1) . Radioactive tracking identified 9 (81.82%) SLNs with a detection sensitivity of 86.67 ± 0.27%. However, there was no statistically significant difference between the detection sensitivities of the fluorescence and radioactive methods (P = 0.374; Table 1 ). This was because radioactive tracking did not identify two SLNs in one of the patients, while accurately identifying all SLNs in rest of the patients. Due to this skewed distribution and the small number of patients, we do not see a statistically significant difference between the detection sensitivities of the two methods.
Tumor Margin Assessment in Human Breast Cancer Patients
The OST GAINS enabled real-time visualization of ICG fluorescence in the tumor tissue (Video 2) and tumor cavity (Video 3). The patient and tumor characteristics are listed in Table 2 . The fluorescence information was projected when requested by the surgeon for visualizing the resected tumor tissue and the cavity. No adverse reactions associated with the use of ICG or the OST GAINS prototype occurred and no postoperative complications were observed. OST GAINS accurately predicted margin status in all three patients and performed better than gross visual inspection and specimen radiography ( Table 2) . Minimal or no fluorescence was observed in the resected tissue or the tumor cavity in patients 1 and 2, and clear margins were predicted based on ICG fluorescence. In patient 3, high fluorescence area was observed on the lumpectomy sample and the edges of the cavity (Fig. 3) , leading to a prediction of positive margins. All margin predictions were confirmed by the final pathology report.
DISCUSSION
Our study demonstrates that the OST GAINS facilitates the integration of FGS in the surgical workflow. The seethrough feature allows direct visualization of the surgical field with the provision of fluorescence information whenever needed. Controllable contrast and opacity of projection allowed optimization of tissue and tumor visualization. Display options for the surgeon include the projection of pseudo-colored fluorescence or superimposed pseudo-colored, fluorescence-color images (Supplemental Fig. 3 ). Our system mirrors the surgeon's view on a remote laptop, and a custom graphical user interface allows realtime modifications of the imaging parameters by a member of the surgical team. 8 This feature enables users to implement the surgeon feedback without disrupting the ongoing surgery. Camera focus was adjusted to compensate for large head movements and to ensure the image was always in focus. Additionally, the built-in fail-safe of the see-through feature can allow surgeons to continue routine surgery in case of system failure to project fluorescence information. All operations were performed under regular OR surgical lights, allowing real-time FGS with minimal disruptions.
The OST GAINS was able to guide complete tumor resection in mice. In pigs, the imaging system allowed noninvasive transcutaneous lymphatic tracking and the identification of LNs using fluorescence guidance only. Recent studies have reported the feasibility of using optical imaging for SLN biopsy and tumor margin assessment. 24, 33, 34 Our results demonstrate the feasibility of detecting SLNs using FGS with identical sensitivity as the standard radioactive tracking method. Using ICG and FGS, we also demonstrate real-time assessment of tumor margins with better accuracy than specimen radiography. The intraoperative margin prediction based on ICG fluorescence was correlated postoperatively with pathology. ICG does not possess tumor specificity via an active cancertargeting mechanism. However, previous studies have shown the feasibility of using ICG fluorescence to detect human tumors in the operating room. 24, 35 ICG can passively accumulate in tumors because of the distorted vasculature and poor lymphatics. Peritumoral injection of ICG, followed by breast massage for a few minutes before imaging in about 15 min postinjection allows the dye to transiently perfuse the periphery of tumors. In addition to enhanced permeation and retention effect, the binding of ICG to blood proteins, such as albumin, in the tumor environment caused by leaky vasculature also is known to facilitate its uptake in tumors. We attribute the detection of positive margins to a combination of factors that includes positive pressure during breast massage, which aids in the distribution and drainage of ICG, poor lymphatics around Although a large patient population is needed to validate the findings of this feasibility study, the encouraging results provide a firm basis to pursue this line of research.
Through its unique wearable design and direct visual access to the surgical field, the OST GAINS overcomes some of the limitations of current standalone and handheld NIR FGS systems. However, comparative evaluation of the OST GAINS prototype and other fluorescence imaging technologies is needed to delineate the strengths of each FGS system for a particular clinical application. The OST GAINS has some limitations. It currently performs final image processing on a laptop, tethering the surgeon to a cart carrying the laptop via a wired connection. Additionally, a mismatch in the perceived distance of the projected fluorescence and actual object distance seen by the surgeon may cause parallax. Efforts are currently underway to ensure complete onboard image processing, with wireless data transmission, as well as to ensure minimal parallax by adjustment of perceived distance of projected fluorescence images.
CONCLUSIONS
The OST GAINS prototype enabled FGS with direct visual access to the surgical field under ambient light. We demonstrated the feasibility of accurate real-time intraoperative SLN biopsy and tumor margin assessment in breast cancer patients without disrupting the surgical workflow.
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